StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ATAI yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $4.31 | $4.15 | -3.71% | 7.9M |
| 05-19 | $4.16 | $3.96 | -4.89% | 4.6M |
| 05-20 | $3.99 | $4.09 | +2.51% | 3.5M |
| 05-21 | $4.06 | $4.33 | +6.65% | 4.0M |
| 05-22 | $4.30 | $4.32 | +0.47% | 5.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $954.00K | $4.09M | $1.55M | $308.00K |
Operating Income | $-30.90M | $-644.06M | $-20.37M | $-102.69M |
Net Income | $-29.78M | $-660.05M | $-26.43M | $-149.27M |
EPS (Diluted) | $-0.08 | $-2.91 | $-0.15 | $-0.93 |
Total Assets | $264.88M | $292.72M | Not available | $159.39M |
Total Liabilities | $66.10M | $70.72M | Not available | $42.83M |
Cash & Equivalents | $43.10M | $85.30M | $58.29M | $17.50M |
Free Cash Flow OCF − CapEx | $-21.09M | $-103.58M | $-18.11M | $-82.44M |
Shares Outstanding | 365.56M | 363.28M | 176.27M | 167.96M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.